Sat Mar 23, 2024 11:33 pm by globalturbo
Sodium Selenate Shows Promise for Patients with Dementia
May 6, 2022 by News Staff / Source
A new study published in the journal Alzheimer’s and Dementia: Translational Research and Clinical Interventions has demonstrated that 12 months of treatment with sodium selenate is safe and well tolerated in patients with behavioral variant frontotemporal dementia, one of the clinical syndromes seen in patients with frontotemporal lobar degeneration and the second most common form of dementia in younger patients.
Vivash et al. investigated the safety and tolerability of treatment with sodium selenate in patients with behavioral variant frontotemporal dementia, and evaluated measures of efficacy to inform future randomized-controlled trials of sodium selenate in patients with behavioral variant frontotemporal dementia. Image credit: Mohamed Hassan.
Behavioral variant frontotemporal dementia (bvFTD) can occur in people as young as 35 years of age.
It is characterized by behavioral disturbances and personality changes, and can be highly disruptive and distressing for both patients and their families.
There are no treatments or cures for bvFTD and typical survival is 5-7 years from diagnosis.
“Our Phase 1 trial showed that sodium selenate is safe and well-tolerated in patients with bvFTD over a period of 12 months,” said Dr. Lucy Vivash, a researcher in the Department of Neuroscience at Monash University, and colleagues.
“The majority of patients receiving sodium selenate showed no change in their cognitive or behavioral symptoms, and reduced rates of brain atrophy over the trial period.”
In almost half of the cases with bvFTD, the damage to the neurons in the brain is caused by the build-up of a protein called tau.
This protein is a major target for research in the prevention and treatment of Alzheimer’s and dementia, as a way to reverse the neurodegeneration caused by this tau accumulation.
“Sodium selenate upregulates an enzyme in the brain that effectively attacks the tau protein,” Dr. Vivash said.
“We have previously shown, in a Phase 2 trial, that patients with mild to moderate Alzheimer’s disease who took sodium selenate experienced less neurodegeneration in those who did not.”
“In addition, those patients in the trial with higher levels of selenium, a breakdown product of sodium selenate, in their bloodstream showed less cognitive decline.”
_____
Lucy Vivash et al. A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer’s Dement 8: e12299; doi: 10.1002/trc2.12299
http://www.sci-news.com/medicine/sodium-selenate-dementia-10782.html?utm_source=feedburner&utm_medium=email
Thanks to: http://www.sci-news.com
May 6, 2022 by News Staff / Source
A new study published in the journal Alzheimer’s and Dementia: Translational Research and Clinical Interventions has demonstrated that 12 months of treatment with sodium selenate is safe and well tolerated in patients with behavioral variant frontotemporal dementia, one of the clinical syndromes seen in patients with frontotemporal lobar degeneration and the second most common form of dementia in younger patients.
Vivash et al. investigated the safety and tolerability of treatment with sodium selenate in patients with behavioral variant frontotemporal dementia, and evaluated measures of efficacy to inform future randomized-controlled trials of sodium selenate in patients with behavioral variant frontotemporal dementia. Image credit: Mohamed Hassan.
Behavioral variant frontotemporal dementia (bvFTD) can occur in people as young as 35 years of age.
It is characterized by behavioral disturbances and personality changes, and can be highly disruptive and distressing for both patients and their families.
There are no treatments or cures for bvFTD and typical survival is 5-7 years from diagnosis.
“Our Phase 1 trial showed that sodium selenate is safe and well-tolerated in patients with bvFTD over a period of 12 months,” said Dr. Lucy Vivash, a researcher in the Department of Neuroscience at Monash University, and colleagues.
“The majority of patients receiving sodium selenate showed no change in their cognitive or behavioral symptoms, and reduced rates of brain atrophy over the trial period.”
In almost half of the cases with bvFTD, the damage to the neurons in the brain is caused by the build-up of a protein called tau.
This protein is a major target for research in the prevention and treatment of Alzheimer’s and dementia, as a way to reverse the neurodegeneration caused by this tau accumulation.
“Sodium selenate upregulates an enzyme in the brain that effectively attacks the tau protein,” Dr. Vivash said.
“We have previously shown, in a Phase 2 trial, that patients with mild to moderate Alzheimer’s disease who took sodium selenate experienced less neurodegeneration in those who did not.”
“In addition, those patients in the trial with higher levels of selenium, a breakdown product of sodium selenate, in their bloodstream showed less cognitive decline.”
_____
Lucy Vivash et al. A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer’s Dement 8: e12299; doi: 10.1002/trc2.12299
http://www.sci-news.com/medicine/sodium-selenate-dementia-10782.html?utm_source=feedburner&utm_medium=email
Thanks to: http://www.sci-news.com
